Suven Life Sciences Intrinsic Value
Suven Life Sciences intrinsic value. Suven Life Sciences (SUVEN) median intrinsic value is ₹454.62 from 2 valuation models (range ₹92–₹455), vs current price ₹306.30 — +48.4% upside (Trading Below Calculated Value), margin of safety 32.6%. For current market price and key ratios, visit Suven Life Sciences share price screener.
SUVEN Valuation Methods Summary — DCF, Graham Number & P/E
Suven Life Sciences intrinsic value across 2 models vs current price ₹306.30 — upside/downside and value range per method. Read Suven Life Sciences dividend payments for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹454.62 | ₹409.16 - ₹500.08 | +48.4% | Book Value/Share: ₹227.31, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹91.89 | ₹82.70 - ₹101.08 | -70.0% | Revenue/Share: ₹12.31, P/S: 2.0x |
SUVEN Intrinsic Value vs Market Price — All Valuation Models
Suven Life Sciences fair value range ₹92–₹455 vs current market price ₹306.30 across 2 valuation models. Compare with SUVEN fundamental valuation to assess whether the stock is under or overvalued.
SUVEN Intrinsic Value Analysis — Undervalued or Overvalued?
Suven Life Sciences median intrinsic value ₹454.62, current price ₹306.30 — Trading Below Calculated Value by 48.4%, margin of safety 32.6%.
What is the intrinsic value of SUVEN?
Based on our comprehensive analysis using 2 different valuation methods, the estimated intrinsic value of Suven Life Sciences (SUVEN) is ₹454.62 (median value). With the current market price of ₹306.30, this represents a +48.4% variance from our estimated fair value.
The valuation range spans from ₹91.89 to ₹454.62, indicating ₹91.89 - ₹454.62.
Is SUVEN undervalued or overvalued?
Based on our multi-method analysis, Suven Life Sciences (SUVEN) appears to be trading below calculated value by approximately 48.4%.
SUVEN Financial Health — Key Ratios vs Industry Benchmarks
Suven Life Sciences financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 39.07 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | -31.1% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | -3331.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.05x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
SUVEN Cash Flow Quality — Operating & Free Cash Flow
Suven Life Sciences operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2026 | ₹-300 Cr | ₹-531 Cr | Negative Cash Flow | 3/10 |
| March 2025 | ₹-155 Cr | ₹-155 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-116 Cr | ₹-116 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-116 Cr | ₹-240 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹-128 Cr | ₹-139 Cr | Negative Cash Flow | 3/10 |